Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC

著者: Melissa D. Barnes, Magdalena A. Taracila, Caryn E. Good, Saralee Bajaksouzian, Laura J. Rojas, David van Duin, Barry N. Kreiswirth, Michael R. Jacobs, Andreas Haldimann, Krisztina M. Papp‐Wallace, Robert A. Bonomo - Antimicrobial Agents and Chemotherapy 2019 被引用: 55

Carbapenem-resistant Enterobacteriaceae (CRE) are resistant to most antibiotics, making CRE infections extremely difficult to treat with available agents. Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) are predominant carbapenemases in CRE in the United States. Nacubactam is a bridged diazabicyclooctane (DBO) β-lactamase inhibitor that inactivates class A and C β-lactamases and exhibits intrinsic antibiotic and β-lactam “enhancer” activity against Enterobacteriaceae .